Skip to main content
placeholder image

Phase I/II study of intraperitoneal iproplatin in patients with minimal residual disease following platinum-based systemic therapy for epithelial ovarian carcinoma.

Journal Article


Abstract


  • 13 patients with minimal residual disease following platinum-based systemic therapy for epithelial ovarian cancer were treated with intraperitoneal iproplatin. A total of three cycles were given at monthly intervals. All patients had minimal residual disease (defined as less than 2 cm in diameter) or positive cytology documented at second look laparotomy following systemic chemotherapy. Iproplatin was administered via a temporary dialysis catheter (n = 11) or a semi permanent Tenckhoff peritoneal dialysis catheter (n = 2). The dose of iproplatin ranged from 150 to 450 mg/m2. No responses to therapy were documented. In this trial the major toxic side effects of iproplatin were thrombocytopenia, diarrhoea, nausea and vomiting. The maximum tolerated dose was 300 mg/m2.

Publication Date


  • 1992

Citation


  • Murphy, D., Lind, M. J., Prendiville, J., Renninson, J., Smith, D. R., Thompson, G., . . . Crowther, D. (1992). Phase I/II study of intraperitoneal iproplatin in patients with minimal residual disease following platinum-based systemic therapy for epithelial ovarian carcinoma.. European journal of cancer (Oxford, England : 1990), 28A(4-5), 870-872. doi:10.1016/0959-8049(92)90137-q

Web Of Science Accession Number


Start Page


  • 870

End Page


  • 872

Volume


  • 28A

Issue


  • 4-5

Abstract


  • 13 patients with minimal residual disease following platinum-based systemic therapy for epithelial ovarian cancer were treated with intraperitoneal iproplatin. A total of three cycles were given at monthly intervals. All patients had minimal residual disease (defined as less than 2 cm in diameter) or positive cytology documented at second look laparotomy following systemic chemotherapy. Iproplatin was administered via a temporary dialysis catheter (n = 11) or a semi permanent Tenckhoff peritoneal dialysis catheter (n = 2). The dose of iproplatin ranged from 150 to 450 mg/m2. No responses to therapy were documented. In this trial the major toxic side effects of iproplatin were thrombocytopenia, diarrhoea, nausea and vomiting. The maximum tolerated dose was 300 mg/m2.

Publication Date


  • 1992

Citation


  • Murphy, D., Lind, M. J., Prendiville, J., Renninson, J., Smith, D. R., Thompson, G., . . . Crowther, D. (1992). Phase I/II study of intraperitoneal iproplatin in patients with minimal residual disease following platinum-based systemic therapy for epithelial ovarian carcinoma.. European journal of cancer (Oxford, England : 1990), 28A(4-5), 870-872. doi:10.1016/0959-8049(92)90137-q

Web Of Science Accession Number


Start Page


  • 870

End Page


  • 872

Volume


  • 28A

Issue


  • 4-5